PMV Pharmaceuticals (PMVP) Competitors $1.41 +0.09 (+6.89%) Closing price 03:58 PM EasternExtended Trading$1.41 0.00 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. CADL, JBIO, TNYA, IMMP, GALT, TECX, HUMA, VYGR, SOPH, and ABEOShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Candel Therapeutics (CADL), Jade Biosciences (JBIO), Tenaya Therapeutics (TNYA), Prima BioMed (IMMP), Galectin Therapeutics (GALT), Tectonic Therapeutic (TECX), Humacyte (HUMA), Voyager Therapeutics (VYGR), SOPHiA GENETICS (SOPH), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Candel Therapeutics Jade Biosciences Tenaya Therapeutics Prima BioMed Galectin Therapeutics Tectonic Therapeutic Humacyte Voyager Therapeutics SOPHiA GENETICS Abeona Therapeutics Candel Therapeutics (NASDAQ:CADL) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Which has more volatility & risk, CADL or PMVP? Candel Therapeutics has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Which has stronger valuation and earnings, CADL or PMVP? Candel Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. Candel Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,649.38-$55.18M-$0.69-8.39PMV PharmaceuticalsN/AN/A-$58.71M-$1.57-0.90 Do insiders & institutionals hold more shares of CADL or PMVP? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer CADL or PMVP? In the previous week, Candel Therapeutics had 3 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 8 mentions for Candel Therapeutics and 5 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.95 beat Candel Therapeutics' score of 0.86 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PMV Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CADL or PMVP more profitable? Candel Therapeutics' return on equity of -41.00% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -41.00% -26.81% PMV Pharmaceuticals N/A -47.94%-43.82% Do analysts rate CADL or PMVP? Candel Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 245.36%. PMV Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 289.79%. Given PMV Pharmaceuticals' higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryCandel Therapeutics beats PMV Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.77M$2.61B$6.04B$10.45BDividend YieldN/A57.78%5.73%4.82%P/E Ratio-0.9022.5685.1427.26Price / SalesN/A751.02590.92134.18Price / CashN/A26.3325.7730.18Price / Book0.425.3812.666.76Net Income-$58.71M$33.06M$3.32B$276.50M7 Day Performance3.75%0.75%0.44%0.88%1 Month Performance14.72%10.22%9.35%8.17%1 Year Performance-5.93%-0.84%79.07%43.52% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals3.2163 of 5 stars$1.41+6.9%$5.50+289.8%-11.4%$74.77MN/A-0.9050News CoverageAnalyst ForecastCADLCandel Therapeutics2.4771 of 5 stars$5.46-0.2%$20.00+266.4%+7.5%$300.30M$120K-7.9360News CoverageJBIOJade Biosciences2.5265 of 5 stars$8.88-2.8%$16.00+80.2%N/A$289.75MN/A-0.2920TNYATenaya Therapeutics2.9942 of 5 stars$1.78+3.2%$6.25+252.1%+11.9%$288.96MN/A-1.85110IMMPPrima BioMed1.1577 of 5 stars$1.97+0.8%$7.00+256.2%-3.4%$288.43MN/A0.002,021Gap UpGALTGalectin Therapeutics1.5861 of 5 stars$4.49+1.0%$6.00+33.8%+88.9%$287.25MN/A-7.019TECXTectonic Therapeutic2.7943 of 5 stars$15.16-0.5%$80.29+429.6%-48.7%$287.16MN/A-3.80120HUMAHumacyte2.7139 of 5 stars$1.79-28.0%$9.29+420.2%-69.3%$281.58M$1.57M-3.95150Analyst ForecastGap DownVYGRVoyager Therapeutics4.0697 of 5 stars$5.02+3.4%$13.25+163.7%-31.9%$276.57M$42.58M-2.70100News CoverageGap DownSOPHSOPHiA GENETICS2.2796 of 5 stars$4.04-0.2%$8.00+97.9%+15.1%$273.70M$65.17M-9.20520ABEOAbeona Therapeutics4.3991 of 5 stars$5.32-0.4%$19.50+266.5%-15.6%$272.80M$400K7.6090News CoverageAnalyst Forecast Related Companies and Tools Related Companies Candel Therapeutics Alternatives Jade Biosciences Alternatives Tenaya Therapeutics Alternatives Prima BioMed Alternatives Galectin Therapeutics Alternatives Tectonic Therapeutic Alternatives Humacyte Alternatives Voyager Therapeutics Alternatives SOPHiA GENETICS Alternatives Abeona Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
